Tyrosine hydroxylase (TH), a crucial enzyme involved in the synthesis of L-dopa, is unstable and has a limited catalytic efficiency, which provide challenges to the pharmaceutical industry's efforts to produce L-dopa enzymatically for the treatment of Parkinson's disease and other neurodegenerative disorders. This evidence concerns the gene TH and Parkinson disease.